HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer

Overview of attention for article published in Frontiers in Molecular Biosciences, March 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 2 news outlets

twitter: 28 X users

Citations

dimensions_citation: 83 Dimensions

Readers on

mendeley: 86 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

El conjugado anticuerpo-fármaco obtiene otra victoria en el cáncer de mama con niveles bajos de HR+/HER2

Espanol.news, 03 Jun 2024

CHICAGO – El conjugado anticuerpo-fármaco (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) mejoró significativamente la…

Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer

MedPage Today, 02 Jun 2024

Meeting Coverage > ASCO Trastuzumab deruxtecan extended its superiority versus chemotherapy into HER2-ultralow by Charles…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.